About: Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19)
Creator	Zhang, Chao Ippolito, Giuseppe Zumla, Alimuddin Maeurer, Markus Agrati, Chiara Bordoni, Veronica Lalle, Eleonora Wang, Fu-Sheng Casetti, Rita Cimini, Eleonora Grassi, Germana Sacchi, Alessandra Zhang, Ji-Yuan Marchioni, Luisa Mariano, Andrea Capobianchi, Maria Antinori, Andrea Fimia, Gian Notari, Stefania Shi, Yufang Song, Jin-Wen Tartaglia, Eleonora Alessandra D'abramo, • Castilletti, • Nicastri, • Piacentini, •
source	Medline; PMC
abstract	SARS-CoV-2 is associated with a 3.4% mortality rate in patients with severe disease. The pathogenesis of severe cases remains unknown. We performed an in-depth prospective analysis of immune and inflammation markers in two patients with severe COVID-19 disease from presentation to convalescence. Peripheral blood from 18 SARS-CoV-2-infected patients, 9 with severe and 9 with mild COVID-19 disease, was obtained at admission and analyzed for T-cell activation profile, myeloid-derived suppressor cells (MDSCs) and cytokine profiles. MDSC functionality was tested in vitro. In four severe and in four mild patients, a longitudinal analysis was performed daily from the day of admission to the early convalescent phase. Early after admission severe patients showed neutrophilia, lymphopenia, increase in effector T cells, a persisting higher expression of CD95 on T cells, higher serum concentration of IL-6 and TGF-β, and a cytotoxic profile of NK and T cells compared with mild patients, suggesting a highly engaged immune response. Massive expansion of MDSCs was observed, up to 90% of total circulating mononuclear cells in patients with severe disease, and up to 25% in the patients with mild disease; the frequency decreasing with recovery. MDSCs suppressed T-cell functions, dampening excessive immune response. MDSCs decline at convalescent phase was associated to a reduction in TGF-β and to an increase of inflammatory cytokines in plasma samples. Substantial expansion of suppressor cells is seen in patients with severe COVID-19. Further studies are required to define their roles in reducing the excessive activation/inflammation, protection, influencing disease progression, potential to serve as biomarkers of disease severity, and new targets for immune and host-directed therapeutic approaches.
has issue date	2020-06-08(xsd:dateTime)
bibo:doi	10.1038/s41418-020-0572-6
bibo:pmid	32514047
has license	cc-by
sha1sum (hex)	9ebda0003ed2fd289bede4454a85b36164cf740b
schema:url	https://doi.org/10.1038/s41418-020-0572-6
resource representing a document's title	Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19)
has PubMed Central identifier	PMC7278239
has PubMed identifier	32514047
schema:publication	Cell Death Differ
resource representing a document's body	covid:9ebda0003ed2fd289bede4454a85b36164cf740b#body_text
is schema:about of	named entity 'convalescence' named entity 'immune response' named entity 'compared' named entity 'severe' named entity 'patients' named entity 'Expansion' named entity 'IN VITRO' named entity 'DISEASE SEVERITY' named entity 'THERAPEUTIC' named entity 'higher' named entity 'immune' named entity 'T-cell' named entity 'engaged' named entity 'immune' named entity 'mild' named entity 'profile' named entity 'disease' named entity 'SARS-CoV-2' named entity 'observed' named entity 'serve' named entity 'phase' named entity 'cytokine' named entity 'inflammatory cytokines' named entity 'SARS-CoV-2' named entity 'TGF-β' named entity 'effector T cells' named entity 'T-cell' named entity 'MDSCs' named entity 'pathogenesis' named entity 'myeloid-derived suppressor cells' named entity 'inflammation' named entity 'coronavirus disease' named entity 'SARS-CoV' named entity 'coronavirus' named entity 'CD8+ T cells' named entity 'flow cytometer' named entity 'neutrophil' named entity 'perforin' named entity 'PMN' named entity 'cytokine' named entity 'COVID' named entity 'written consent' named entity 'Beckman Coulter' named entity 'inflammation' named entity 'T-cell' named entity 'PBMC' named entity 'CD14' named entity 'tracer' named entity 'COVID-19 disease' named entity 'venous blood' named entity 'infection' named entity 'Beckman Coulter' named entity 'adaptive immune' named entity 'reduction of inflammation' named entity 'lymphopenia' named entity 'T-cell'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software